{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:49:10Z","timestamp":1789224550245,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Biopharma Co, Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Tepotinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. The objective of this post-marketing surveillance (PMS) was to assess the safety and effectiveness of tepotinib in general clinical practice in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter, non-interventional PMS included patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations who received at least one dose of tepotinib. The primary endpoint was the incidence of adverse drug reactions (ADRs) identified as safety specifications (SS) for tepotinib according to the Japanese Risk Management Plan (ADRs of SS); i.e. interstitial lung disease (ILD), fluid retention, hepatic function disorder, renal impairment, and QT interval prolongation (classified by preferred term). The secondary endpoints were ADRs of SS in patient subgroups and the effectiveness of tepotinib in clinical practice. In total, 147 patients were included (median age 72.0\u00a0years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The incidence of ILD, fluid retention, hepatic function disorder, and renal impairment was 7.5%, 47.6%, 13.6%, and 36.1%, respectively; incidence of grade \u22653 ADRs of SS were 3.4%, 9.5%, 4.8%, and 2.7%, respectively. No instances of QT interval prolongation occurred. Four patients (2.7%) died due to ILD. The objective response rate was 51.0% [95% confidence interval (CI) 42.7, 59.3] and disease control rate was 77.6% (95% CI 69.9, 84.0).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tepotinib was generally well tolerated and effective in patients with NSCLC and METex14 skipping alterations in general clinical practice in Japan; no new safety issues or concerns were identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf099","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T22:19:13Z","timestamp":1751062753000},"page":"1152-1161","source":"Crossref","is-referenced-by-count":4,"title":["Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with <i>METex14<\/i> skipping alterations: post-marketing surveillance in Japan"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, Kanagawa Cancer Center , 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515,","place":["Japan"]},{"name":"Clinical Research Center , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ogura","sequence":"additional","affiliation":[{"name":"PMS Planning & Strategy, Merck Biopharma Co, Ltd . (an affiliate of Merck KGaA), 1.3.1 Azabudai, Minato-ku, Tokyo 106-0041,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Global Research & Development, Clinical Measurement Sciences, Biostatistics, Merck Biopharma Co, Ltd . (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Kojima","sequence":"additional","affiliation":[{"name":"Global Patient Safety Japan, Merck Biopharma Co, Ltd . (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingbing","family":"Song","sequence":"additional","affiliation":[{"name":"Global Development Operations Japan, R&D, Merck Biopharma Co, Ltd . (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Horii","sequence":"additional","affiliation":[{"name":"Oncology Medical Affairs, Merck Biopharma Co, Ltd . (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine , 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2025100708164894800_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025100708164894800_ref2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025100708164894800_ref3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/cas.14368","article-title":"A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients","volume":"111","author":"Sekine","year":"2020","journal-title":"Cancer Sci"},{"key":"2025100708164894800_ref4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cllc.2022.07.012","article-title":"Asian thoracic oncology research group (ATORG) expert consensus statement on MET alterations in NSCLC: Diagnostic and therapeutic considerations","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2025100708164894800_ref5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100708164894800_ref6","doi-asserted-by":"publisher","first-page":"S784","DOI":"10.1016\/S1556-0864(21)02000-1","article-title":"Prevalence and clinical outcomes of MET exon 14 (METex14) skipping in patients with advanced NSCLC: a systematic literature review","volume":"16","author":"Cortot","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100708164894800_ref7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025100708164894800_ref8","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/cancers14153784","article-title":"A prospective validation study of lung cancer gene panel testing using cytological specimens","volume":"14","author":"Morikawa","year":"2022","journal-title":"Cancer"},{"key":"2025100708164894800_ref9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jtho.2015.10.005","article-title":"Multiplex diagnosis of oncogenic fusion and MET exon skipping by molecular counting using formalin-fixed paraffin embedded lung adenocarcinoma tissues","volume":"11","author":"Sunami","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025100708164894800_ref10","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025100708164894800_ref11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"2025100708164894800_ref12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100708164894800_ref13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100708164894800_ref14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14\u2013skipping non\u2013small cell lung cancer: Long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025100708164894800_ref15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cllc.2022.03.002","article-title":"Safety of tepotinib in patients with MET exon 14 skipping NSCLC and recommendations for management","volume":"23","author":"Veillon","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2025100708164894800_ref16","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1111\/bcp.14807","article-title":"Achievements and challenges of the Sakigake designation system in Japan","volume":"87","author":"Tanaka","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025100708164894800_ref17","author":"Merck","year":"2020"},{"key":"2025100708164894800_ref18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/jjco\/hyab072","article-title":"Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the phase II VISION study","volume":"51","author":"Sakai","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2025100708164894800_ref19","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/cas.16107","article-title":"Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the phase II VISION study","volume":"115","author":"Morise","year":"2024","journal-title":"Cancer Sci"},{"key":"2025100708164894800_ref20","author":"The Japan Lung Cancer Society","year":"2023"},{"key":"2025100708164894800_ref21","author":"Pharmaceuticals and Medical Devices Agency","year":"2020"},{"key":"2025100708164894800_ref22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","article-title":"Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: A clinical review","volume":"23","author":"Cortot","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2025100708164894800_ref23","author":"European Medicines Agency","year":"2022"},{"key":"2025100708164894800_ref24","author":"United States Food and Drug Administration","year":"2020"},{"key":"2025100708164894800_ref25","author":"Pharmaceuticals and Medical Devices Agency","year":"2020"},{"key":"2025100708164894800_ref26","author":"Pharmaceuticals and Medical Devices Agency","year":"2024"},{"key":"2025100708164894800_ref27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jtho.2023.09.1444","article-title":"Brief report: Tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to \u201cfalse\u201d decreases in renal function","volume":"19","author":"Chen","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2025100708164894800_ref28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/ckj\/sfac180","article-title":"Pseudo-acute kidney injury secondary to tepotinib","volume":"16","author":"Wijtvliet","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025100708164894800_ref29","author":"United States Food and Drug Administration","year":"2021"},{"key":"2025100708164894800_ref30","author":"Drug Safety Division of the Pharmaceuticals and Lifestyle Health Bureau MoH, Labour and Welfare of Japan","year":"2019"},{"key":"2025100708164894800_ref31","volume-title":"Clinical Features of Tepotinib-induced Interstitial Lung Disease under Post marketing Setting_ Interim Analysis 2 [abstract O24\u20135]","author":"Kato","year":"2024"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/10\/1152\/63537708\/hyaf099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/10\/1152\/63537708\/hyaf099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:16:53Z","timestamp":1759839413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/10\/1152\/8170062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf099","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,20]]}}}